Neuroendocrine Neoplasms of the Lung: A Prognostic Spectrum

Asamura, Hisao; Kameya, Toru; Matsuno, Yoshihiro; Noguchi, Masayuki; Tada, Hirohito; Ishikawa, Yuichi; Yokose, Tomoyuki; Jiang, Shi Xu; Inoue, Takeshi; Nakagawa, Ken; Tajima, Kinuko; Nagai, Kanji

doi:10.1200/jco.2005.04.1202

Cited by 427 publications

(366 citation statements)

References 20 publications

Supporting

Mentioning

342

Contrasting

Unclassified

Order By: Relevance

“…For TC, AC, LCNEC and SCLC, the male proportions were 52.2%, 80.5%, 100% and 76.5%. These results were fairly comparable to the results of a recent large-scale multi-institute study by Asamura et al (Asamura et al, 2006). The general present symptoms of these patients included cough (63.1%), hemoptysis (26.7%), dyspnea (15.9%), chest pain (13.6%), fever (6.3%) and headache (2.3%).…”

Section: Discussionsupporting

confidence: 89%

“…It still exists controversy regarding the independent prognostic factors for overall survival (OS). Several authors pointed out that lymph node involvement, histology and tumor size were the important and independent factors influencing the prognosis (Lim et al, 2005;Asamura et al, 2006;Filosso et al, 2013). The aim of this study was to describe the clinical characteristics and independent prognostic factors of Chinese patients with pulmonary NET.…”

Section: Analysis On the Characteristics And Prognosis Of Pulmonarymentioning

confidence: 99%

See 1 more Smart Citation

Analysis on the Characteristics and Prognosis of Pulmonary Neuroendocrine Tumors

Hu²,

Sun³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 89%

Section: Analysis On the Characteristics And Prognosis Of Pulmonarymentioning

confidence: 99%

Analysis on the Characteristics and Prognosis of Pulmonary Neuroendocrine Tumors

Hu²,

Sun³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…52 Difficulty of diagnosis in high-grade neuroendocrine carcinoma is thought to occur as a result of variety of reasons, including the continuum of cell size and morphology between small cell carcinoma and large cell neuroendocrine carcinoma, and poor sampling and tissue artifacts. 53 We propose that one of the main reasons why there are differences between observers in histological diagnosis of high-grade neuroendocrine carcinoma may be the presence of tumors shown in Figure 1c in this study.…”

Section: Discussionmentioning

confidence: 99%

Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis

et al. 2006

View full text Add to dashboard Cite

The distinction between pulmonary large cell neuroendocrine carcinoma and small cell carcinoma is difficult in some cases. Some propose that these carcinomas should be classified as one high-grade neuroendocrine carcinoma. We examined biological features of small cell carcinoma (n ¼ 23), large cell neuroendocrine carcinoma (n ¼ 17), and classic large cell carcinoma (n ¼ 12). The average ratio of nuclear diameter of the tumor cells to that of lymphocytes for small cell carcinoma was smaller than that for large cell neuroendocrine carcinoma (Po0.0001). The frequencies of the expressions of CD56, mASH1, TTF-1, and p16 were higher and that of NeuroD was lower in small cell carcinoma than in large cell neuroendocrine carcinoma. The frequency of loss of heterozygosity at 3p was higher in high-grade neuroendocrine carcinomas than in classic large cell carcinoma (P ¼ 0.0002). Allelic losses at D5S422 (5q33) were more frequent in small cell carcinoma than in large cell neuroendocrine carcinoma (P ¼ 0.0091). Mean fractional regional loss indices of the tumors were 0.38, 0.65, and 0.72 for patients with classic large cell carcinoma, large cell neuroendocrine carcinoma, and small cell carcinoma, respectively (P ¼ 0.0003). Five-year overall survivals of patients with classic large cell carcinoma, large cell neuroendocrine carcinoma and small cell carcinoma in stage I were 67, 73, 60%, respectively. Patients with NeuroD expression had better survivals, and those with p63 expression had poorer survivals in large cell neuroendocrine carcinoma. Patients with TTF-1 expression had poorer survivals in small cell carcinoma. Our data suggest that large cell neuroendocrine carcinoma and small cell carcinoma are different morphologically, phenotypically, and genetically, although there are some overlapping features. Although further studies are needed to analyze the biological behavior of high-grade neuroendocrine carcinomas including sensitivity to chemotherapy, the pathological distinction of large cell neuroendocrine carcinoma from small cell carcinoma may be necessary to treat the patients with neuroendocrine tumors.

show abstract

“…12,20,21 The present study is a systematic review and a meta-analysis of trials to assess the efficacy of targeted agents in patients with advanced NET. NETs are a heterogeneous disease arising from various primary sites such as the small intestine or other sites of the gastrointestinal tract, and the lung, 30,31 therefore their management is complicated by a different clinical presentations, clinical disease course, symptoms and degree of aggressiveness. 3 In our analysis, target agents improved the PFS and OS of advanced NETs patients compared with control group.…”

Section: Discussionmentioning

confidence: 99%

Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis

Roviello

Zanotti

Venturini

et al. 2016

Cancer Biology & Therapy

View full text Add to dashboard Cite

Background: Several randomized phase III trials in neuroendocrine tumors (NETs) showed the clinical role of new targeted agents and their impact on tumor response and outcome of whose patients affected by advanced NET. In this study, we summarize the available clinical data related to clinical efficacy of targeted therapies in the treatment of advanced NETs. Methods: A meta-analysis of randomized studies in accordance with the PRISMA guidelines was performed after searching the databases of PubMed, the Cochrane Library, and the ASCO University Meeting for relevant publications. Results: One thousand 9 hundred and 8 cases were included in the meta-analysis; among these, 1012 were in the experimental arm and 896 were in the control arm. The pooled analysis of the use of target agents in NETs revealed significantly increased of progression free survival compared to control group (hazard ratio D 0.59, 95% CI:0.42-0.84; P D 0.003). Subgroup analysis of patients according to tumor site showed a difference in favor of pancreatic neuroendocrine tumors. Moreover, targeted therapies improved the overall survival (hazard ratio D 0.79, 95%CI: 0.63-0.98; P D 0.03), and response rate (hazard ratio D 3.33, 95% CI 2.02-5.49; P < 0.00001) in all types of NETs. Conclusion: Our analysis supports the routine use of targeted agents for treatment of neuroendocrine tumors with particular regards to the pancreatic neuroendocrine tumors.

show abstract

Neuroendocrine Neoplasms of the Lung: A Prognostic Spectrum

Abstract: The grade of malignancy of NE tumors was upgraded in the following order: TC, AC, LCNEC, and SCLC. No prognostic difference was noted between LCNEC and SCLC. The high-grade NE histology uniformly indicated poor prognosis regardless of its histologic type.

Cited by 427 publications

References 20 publications

Analysis on the Characteristics and Prognosis of Pulmonary Neuroendocrine Tumors

Analysis on the Characteristics and Prognosis of Pulmonary Neuroendocrine Tumors

Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis

Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis

Contact Info

Product

Resources

About